Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease

American Journal of Gastroenterology

Volumn 112, Issue 10, 2017, Pages 1584-1592

  Khanna, Reena ^a,b   Zou, GuangYong ^a,b   Stitt, Larry ^a   Feagan, Brian G ^a,b   Sandborn, William J ^a,c   Rutgeerts, Paul ^d   McDonald, John W D ^a   Dubcenco, Elena ^a   Fogel, Ronald ^e   Panaccione, Remo ^f   Jairath, Vipul ^a,b,g   Nelson, Sigrid ^a   Shackelton, Lisa M ^a   Huang, Bidan ^h   Zhou, Qian ^g   Robinson, Anne M ^h   Levesque, Barrett G ^a,c   D'Haens, Geert ^a,i  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Digestive Health Center of Michigan   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h ABBVIE INC   (United States)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT-REPORTED OUTCOME; PREDICTION; PRIORITY JOURNAL; RELIABILITY; STENOSIS; VIDEORECORDING; CONTROLLED STUDY; DRUG MONITORING; GASTROINTESTINAL ENDOSCOPY; METHODOLOGY; MIDDLE AGED; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; STANDARDS; STATISTICS; STATISTICS AND NUMERICAL DATA;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; DRUG MONITORING; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; VIDEO RECORDING;

EID: 85009165610     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.580     Document Type: Article

References (19)

1. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Aff ections Infl ammatoires du Tube Digestif (GETAID). Gut 1989 ; 30 : 983-9.
2. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplifi ed endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest Endosc 2004 ; 60 : 505-12.
3. Khanna R, Zou G, D'Haens G, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 2016 ; 65 : 1119-25.
4. Gottlieb K, Travis S, Feagan B, et al. Central reading of endoscopy endpoints ininfl ammatory bowel disease trials. Infl amm Bowel Dis 2015 ; 21 : 2475-82.
5. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013 ; 145 : 149-57.e2.
6. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012 ; 142 : 1102-11.
7. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 ; 70 : 439-44.
8. Pigott T. A review of methods for missing data. Educ Res Eval 2001 ; 7 : 353-83.
9. Dubcenco E, Zou GY, Stitt L, et al. Effect of standardized scoring conventions on inter-rater reliability in the endoscopic evaluation of Crohn's disease. J Crohn's Colitis 2016 ; 10 : 1006-14.
10. de Vet HCW, Terwee CB, Mokkink LB, et al. Measurement in Medicine: Practical Guides to Biostatistics and Epidemiology Cambridge University Press : Cambridge, 2011.
11. Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: The development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2015 ; 41 : 77-86.
12. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991 ; 12 : 142s-58s.
13. Gasink CFJ, Gao LL, Chan D, et al. Evaluation of an interim Crohn's disease outcome measure (PRO-2) based on two patient-reported components (stool frequency, abdominal pain) of the Crohn's Disease Activity Index (CDAI) in the ustekinumab CERTIFI Study. J Crohn's Colitis 2015 ; 9 ( Suppl 1 ): S158.
14. Zou GY. Quantifying responsiveness of quality of life measures without an external criterion. Qual Life Res 2005 ; 14 : 1545-52.
15. Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing responsiveness: A critical review and recommendations. J Clin Epidemiol 2000 ; 53 : 459-68.
16. Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013 ; 145 : 978-86.
17. Rutgeerts P, Reinisch W, Colombel J, et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: Comparison using data from the EXTEND trial. Gastrointest Endosc 2016 ; 83 : 188-97.
18. Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013 ; 62 : 201-8.
19. Peyrin-Biroulet P, Sandborn W, Sands BE, et al. Selecting therapeutic targets in infl ammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015 ; 110 : 1324-38.